The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
April 17th 2025
Though the rate of coronary artery lesions decreased across both cohorts of this trial of children with Kawasaki disease, there were no differences in lesion reduction between those receiving intravenous immunoglobulin (IVIG) alone and those receiving IVIG with aspirin.
How to Address Customer Concerns Regarding Uncovered Prescriptions in the Pharmacy Setting
July 16th 2021Since pharmacy is a service business, the required process of communicating and educating customers, working closely with physicians, and navigating relief programs can help patients customers address the problems and stress of receiving a denial by their insurance company.
Read More
The American Society of Health-System Pharmacists’ (ASHP) first annual survey of health-system specialty pharmacies (HSSPs) offered insights into the concerns of specialty pharmacists and provided an opportunity for professionals in the field to outline a potential future for specialty pharmacy.
Read More
Communicating With Care and Compassion: A Key to Unlocking Health Care Disparity
July 15th 2021White continued to discuss how being self-aware, using the right language, modeling behaviors that support belonging, and fostering an environment with psychological safety is the goal as a a health care provider.
Read More
Pharmacist Medication Insights: Tepotinib for Non-Small Cell Lung Cancer
June 21st 2021Earlier this year, the FDA granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc) for the treatment of adults with metastatic non-small cell lung cancer who are harboring MET exon 14 skipping alterations.
Watch
The Multiple Myeloma Treatment Pipeline and Specialty Pharmacy
June 15th 2021Dealing with a cancer diagnosis is difficult, but patients with MM have reason to be hopeful. Survival rates are on the rise, and a robust pipeline of promising immunotherapies and novel treatment options are in development.
Read More
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer
May 21st 2021In a trial of amivantamab-vmjw, investigators found an overall response rate of 40% among patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 20 insertion mutations.
Read More